Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II capecitabine plus cisplatin for recurrent HER2‑negative gastric cancer after S‑1 adjuvant therapy (T-CORE1102)
jRCTs021180013Phase 2Completed
- Sponsor
- Tohoku Clinical Oncology Research and Educational Society
- Start
- Feb 2012
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine and cisplatin in gastric adenocarcinoma, sponsored by Tohoku Clinical Oncology Research and Educational Society. Primary endpoint: Progression-Free Survival. Started Feb 2012; status: completed.
02
Drugs
capecitabinecisplatin
03
Conditions
gastric adenocarcinoma
Beyond the preview
Go deeper on jRCTs021180013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021180013.